Esperion Therapeutics, Inc.
ESPR evidence brief
What we can confirm
- BioSniper Score:
- 3.0 / 10
- Market Cap:
- $819.5M
- Cash Runway:
- 16.9 mo
What it means
What to watch
Prepared research question
What matters most for ESPR—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · ESPR
Esperion Therapeutics, Inc. (ESPR) is a commercial-stage biopharmaceutical company focused on developing and marketing oral, non-statin medicines for cardiovascular disease, primarily bempedoic acid products NEXLETOL and NEXLIZET.
Key risk: Negative equity
BioSniper Score
Based on 4 of 6 signals
Financial data as of Mar 31, 2026.
Tracking 2 catalysts · 2 FDA decisions for Esperion Therapeutics, Inc..
Esperion Therapeutics, Inc. (ESPR) is a commercial-stage biopharmaceutical company focused on developing and marketing oral, non-statin medicines for cardiovascular disease, primarily bempedoic acid products NEXLETOL and NEXLIZET.
- Cash & equivalents of $156.2M as of 2026-03-31 [sec].
- Total revenue of $80.1M and net income of -$25.2M for the period ending 2026-03-31 [sec].
- Shareholders' equity of -$307.9M as of 2026-03-31 [sec].
- Commercializing FDA-approved NEXLETOL and NEXLIZET in the U.S. [sec_mda · as of 2026-05-08].
- Otsuka Pharmaceutical received Japanese approval for NEXLETOL in September 2025 [sec_mda · as of 2026-05-08].
What works
- Approved products NEXLETOL and NEXLIZET provide a non-statin LDL-C lowering option for patients with cardiovascular disease [sec_mda · as of 2026-05-08].
- International expansion underway: Japanese approval and NHI pricing secured, Canadian approval obtained, and filings in Israel and Australia [sec_mda · as of 2026-05-08].
- Corporate performance goals for 2025 were fully met, including commercial sales targets and pipeline advancement [sec · filed 2026-04-16].
What to weigh
- Net income was negative at -$25.2M for the three months ended 2026-03-31 [sec].
- Shareholders' equity is deeply negative at -$307.9M as of 2026-03-31 [sec].
- The company may need additional financing to support operations and development; failure to raise capital could have a material adverse effect [sec_mda · as of 2026-05-08].
- Net cash used in operating activities was $27.7M for the three months ended March 31, 2026 [sec_mda · as of 2026-05-08].
From the filings
Quoted directly from source documents.
Commercialization of NEXLETOL and NEXLIZET in the U.S.
“commercializing NEXLETOL and NEXLIZET in the U.S.”
SEC MD&A · May 8, 2026
Catalyst timeline
- 2040-06-19 · Patent_Expiry · BEMPEDOIC ACID — Patent expiry for NDA211616; may open market to generic competition.
- 2040-06-19 · Patent_Expiry · BEMPEDOIC ACID; EZETIMIBE — Patent expiry for NDA211617; may open market to generic competition.
Risks & what to watch (3)›
Key risks
- Negative equity — Shareholders' equity of -$307.9M indicates accumulated losses exceed capital [sec].
- Operating cash burn — Net cash used in operations was $27.7M in Q1 2026, requiring ongoing financing [sec_mda · as of 2026-05-08].
- Financing dependency — Company may need additional financing; failure to raise capital could have material adverse effect [sec_mda · as of 2026-05-08].
What to watch
- U.S. net sales performance of NEXLETOL/NEXLIZET, weighted at 45% of corporate goals [sec · filed 2026-04-16].
- Progress of pediatric program and international expansion, including Canadian NEXLIZET approval expected first half 2026 [sec_mda · as of 2026-05-08].
- Cash management: goal to keep cash used in operations within $215M budget [sec · filed 2026-04-16].
- Pipeline advancement of next-generation ACLY inhibitors and early-stage assets [sec_mda · as of 2026-05-08].
Sources: Catalysts · Pipeline · SEC filings · SEC MD&A · Generated October 4, 2026 · How we verify sources →
Run Esperion Therapeutics, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Esperion Therapeutics, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 4 of 6 signals · derived from public data
Pipeline inputs are unavailable for this score. It uses only the available signals shown below.
16.9 months
OCF -$28M · Net income -$25M
No tracked pipeline phase
No tracked pipeline candidates
2 upcoming, next in ~4996d
0 buys · 3 sells (180d)
Runway
Catalysts
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
205
Total value held
$474.9M
| Holder | Shares | Value |
|---|---|---|
| blackrock, inc. | 17,852,427 | $48.9M |
| wasatch advisors lp | 15,768,897 | $43.2M |
| two seas capital lp | 11,394,833 | $31.2M |
| orbimed advisors llc | 10,570,300 | $29.0M |
| vanguard capital management llc | 10,433,760 | $28.6M |
| two sigma investments, lp | 9,458,779 | $25.9M |
| marshall wace, llp | 7,075,083 | $19.4M |
| state street corp | 7,055,794 | $19.3M |
| d. e. shaw & co., inc. | 6,540,785 | $17.9M |
| geode capital management, llc | 5,955,739 | $16.3M |
Showing top 10 of 205 institutional holders of Esperion Therapeutics, Inc.. Open the full 13F history after sign-in.
Short Interest
as of Apr 20, 2026- % of float
- 13.0%
- Days to cover
- 5.9
- Shares short
- 33,129,776
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
ESPR short interestGovernance
Frequently asked questions
What is the AI investment thesis for Esperion Therapeutics, Inc.?
Esperion Therapeutics, Inc. (ESPR) is a commercial-stage biopharmaceutical company focused on developing and marketing oral, non-statin medicines for cardiovascular disease, primarily bempedoic acid products NEXLETOL and NEXLIZET.
What is Esperion Therapeutics, Inc.'s next catalyst?
Esperion Therapeutics, Inc.'s next tracked catalyst is a Patent_Expiry event — "Patent_Expiry: NDA211616" — expected June 19, 2040.
Who is the CEO of Esperion Therapeutics, Inc.?
Mr. Sheldon L. Koenig M.B.A. is the chief executive officer of Esperion Therapeutics, Inc. (ESPR).
Where is Esperion Therapeutics, Inc. headquartered?
Esperion Therapeutics, Inc. (ESPR) is headquartered in Ann Arbor, MI, United States.
What therapeutic areas does Esperion Therapeutics, Inc. focus on?
Esperion Therapeutics, Inc. develops therapies across Cardiovascular, Metabolic.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.